Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/8jk1mn61

ANTIMICROBIAL STEWARDSHIP: STRATEGIES TO COMBAT DRUG RESISTANCE AND IMPROVE PATIENT OUTCOMES

Dr. J. Arunkumar[1], Dr. R. Shanmugapriya[2], Dr. S. Rathipriya[3] and Dr. S. Kovendhan[4*]

[1]Associate Professor, Department of Pharmacology, K.A.P Viswanatham Government Medical College, Tiruchirapalli, Tamil Nadu, India.
[2]Assistant Professor, Department of Biochemistry, Government Medical College and Hospital, Annamalai Nagar, Cuddalore Tamil Nadu, India.
[3]Assistant Professor, Department of Obstetrics and Gynaecology, Government Dindigul Medical College, Tamil Nadu, India.
[*4]Assistant Professor, Department of Microbiology, Government Dindigul Medical College, Tamil Nadu, India.

***Corresponding author:** Dr. S. Kovendhan
*Department of Microbiology Government Dindigul Medical College, Tamil Nadu, India

Abstract
Antimicrobial resistance (AMR) is a developing worldwide health issue that reduces the effectiveness of antimicrobial medicines, increasing morbidity, mortality, and healthcare expenditures. The overuse and misuse of antimicrobials in both human and veterinary medicine has hastened the emergence of resistant bacteria. antibiotic stewardship (AMS) initiatives have evolved as an important approach to combat AMR by optimizing antibiotic use, assuring appropriate dosing, and reducing resistance. These initiatives use a multimodal approach, encompassing leadership support, formulary management, evidence-based prescribing recommendations, ongoing education, surveillance, and infection control measures. Antibiotic de-escalation, dosage modification, and therapy length are all AMS measures designed to limit needless antimicrobial exposure while improving patient outcomes. Despite the effectiveness of AMS programs, difficulties persist, particularly in resource-constrained areas, such as a lack of diagnostic tools, resistance from healthcare providers, and financial limitations. The impact of AMS programs includes lower mortality rates, shorter hospital stays, enhanced resistance profiles, and cost savings. The future of AMS programs depends on the incorporation of sophisticated technology such as artificial intelligence, quick diagnostics, genetic surveillance, and worldwide collaboration. These advances have the potential to further optimize antibiotic use while also addressing the global concern of antimicrobial resistance.

Keywords: Antimicrobial Resistance (AMR), Antimicrobial Stewardship (AMS), Antibiotic Optimization, Resistance Patterns, Global Health

Introduction
Antimicrobial resistance (AMR) is a serious global health concern that occurs when microorganisms such as bacteria, viruses, fungi, and parasites discover methods to withstand the effects of medications that were once successful at killing or suppressing their growth. These resistant pathogens are becoming increasingly difficult to cure, resulting in prolonged sickness,

higher healthcare expenses, and higher morbidity and mortality [1-3]. While resistance to antimicrobial agents has evolved naturally over millions of years as microorganisms adapt to a changing environment, human activities, particularly the overuse and misuse of antimicrobial agents, have accelerated the development of resistant pathogens [4]. The overuse of antibiotics in both human and veterinary medicine is a major cause of AMR [5]. Inappropriate prescribing, such as using antibiotics for viral infections or for diseases for which they are not indicated, contributes to resistance [6]. Furthermore, patients frequently fail to complete prescribed antibiotic treatments, allowing surviving germs to potentially develop resistance [7]. In agriculture, using antibiotics in livestock to stimulate growth or prevent diseases in healthy animals contributes to the development of resistant bacteria, which can subsequently spread to humans via the food chain or direct contact with animals [8]. Similarly, the misuse of antifungal and antiparasitic medications, frequently without sufficient diagnostic testing, has resulted in resistance in fungi and parasites [9].
The effects of AMR are serious and far-reaching. According to the World Health Organization (WHO), if left unchecked, AMR could cause an estimated 10 million deaths per year by 2050, surpassing cancer as the main cause of mortality worldwide [10]. Resistant infections can inflict a significant strain on healthcare systems, resulting in longer hospital admissions, more intense care, and the use of more expensive, toxic, and ineffective medications [11]. To address this growing concern, antimicrobial stewardship (AMS) initiatives have been created as a strategic approach to optimizing the use of antimicrobial drugs [12]. These programs seek to guarantee that patients receive the most appropriate antibiotic, at the optimum dose, and for the optimal duration, all while reducing the risk of resistance. AMS programs often entail a collaborative effort by doctors, pharmacists, microbiologists, infection control experts, and hospital administrators to promote evidence-based prescribing practices, provide rapid diagnostic support, and track antimicrobial use across healthcare settings [13, 14]. The purpose of AMS is not only to reduce needless antibiotic use, but also to educate healthcare practitioners and the general public about the dangers of overprescribing and the significance of utilizing antimicrobials responsibly [15]. One of the core ideas of AMS is the concept of "antibiotic stewardship," which aims to strike a balance between the demand for effective treatment and the need to conserve the efficacy of current antimicrobial medicines for future generations [16]. AMS programs have been found to enhance patient outcomes by decreasing the number of illnesses caused by resistant microbes, cutting healthcare expenses, and shortening the time of antibiotic therapy. Additionally, these initiatives help to reduce adverse medication reactions and prevent complications linked with antibiotic use [17]. AMS programs have benefits that extend beyond hospital settings; in outpatient and community-based settings, they can reduce needless antibiotic prescriptions, lower the occurrence of antibiotic-related adverse effects, and slow the spread of resistance in the community [18]. While the deployment of AMS programs has had excellent results, a number of problems persist. These include limited resources in low- and middle-income countries, healthcare provider opposition to modifying prescribing habits, a lack of diagnostic tools for quick infection detection, and challenges in monitoring and tracking antimicrobial use [19]. Overcoming these obstacles will necessitate a collaborative, multidisciplinary approach to improving the effectiveness of AMS initiatives, addressing gaps in healthcare infrastructure, and ensuring that antimicrobial medicines remain viable tools for treating infections [20]. The purpose of this review is to examine the main tactics used by AMS programs, their effects on patient outcomes, and the difficulties encountered during implementation. We'll also talk about the use of new diagnostic and treatment techniques, policy formulation, education, and surveillance. This evaluation seeks to offer a thorough grasp of how AMS can lessen the escalating threat of AMR and enhance healthcare outcomes globally by looking at these tactics and difficulties.

The Fundamental Elements of Programs for Antimicrobial Stewardship

Programs for AMS are complex endeavours aimed at maximizing the use of antibiotics and thwarting the escalating threat of AMR. These programs consist of a number of essential elements that complement one another to encourage the prudent use of antibiotics, guaranteeing that patients are given the proper medication at the right dosage for the right amount of time [21]. Depending on the context—hospitals, outpatient clinics, or long-term care institutions, for example—AMS programs may have different components, but they typically share a number of important tactics and procedures. Multidisciplinary teams made up of infectious disease experts, microbiologists, pharmacists, physicians, and hospital managers frequently carry out these elements; each member is essential to the program's success [22]. This table 1 gives an overview of each key component and its role in an effective AMS program.

Table: 1 The core components of Antimicrobial Stewardship Programs

Component	Objective	Strategy	Ref
Leadership and Governance	Ensure integration of AMS activities into clinical workflows and policies.	Establish strong leadership support and governance structures. Allocate resources for training and monitoring.	[23]
Formulary Management	Optimize antimicrobial selection and reduce resistance.	Implement antibiotic restrictions, promote narrow-spectrum agents, and use de-escalation strategies.	[24]
Antibiotic Prescribing Guidelines	Provide evidence-based guidance to optimize antibiotic therapy.	Develop clear, evidence-based prescribing protocols on choice, dosing, and duration of therapy.	[25]
Education and Training	Enhance clinician knowledge and adherence to appropriate antimicrobial practices.	Deliver continuous education on infection signs, antimicrobial misuse, and resistance patterns.	[26]
Surveillance and Monitoring	Monitor antimicrobial use and resistance to guide interventions and identify trends.	Collect data on prescribing practices and resistance patterns. Use findings to adjust treatment approaches.	[27]
Feedback and Audit	Ensure adherence to AMS guidelines and improve prescribing habits.	Conduct regular audits and provide feedback on antimicrobial usage and appropriateness.	[28, 29]
Infection Control and Prevention	Minimize the spread of resistant pathogens in healthcare settings.	Implement IPC measures like hand hygiene, isolation precautions, and environmental cleaning.	[30]

Strategies to Optimize Antibiotic Use

Optimizing antibiotic use in AMS programs is critical for preventing the development of AMR and improving patient outcomes. Several measures are used to guarantee that antibiotics are provided correctly, at the appropriate dose, duration, and clinical context. These initiatives seek to limit unnecessary or inappropriate antibiotic usage, slow the emergence of resistance, and maximize the therapeutic effects of antimicrobials. AMS programs commonly use the following important strategies:

1. Antibiotic Stewardship Guidelines and Protocols

One of the most essential tactics for optimizing antibiotic use is to develop clear, evidence-based clinical guidelines and treatment protocols. These guidelines assist healthcare providers in selecting the most appropriate antibiotic based on the infection, the patient's medical history, and local resistance patterns. For example, evidence-based procedures for common illnesses like urinary tract infections, pneumonia, and sepsis offer an organized approach to antibiotic selection, dose, and duration. These guidelines help to reduce the overuse of broad-spectrum antibiotics and promote the use of narrower-spectrum medicines whenever possible, thereby minimizing the risk of resistance [31-33].

2. Antibiotics De-escalation

Antibiotic de-escalation is the technique of starting with broad-spectrum antibiotics in the early phases of treatment based on clinical presentation and subsequently restricting the antibiotic options once culture findings and susceptibility testing are known. This technique ensures that patients receive the most suitable antibiotic therapy while avoiding the overuse of broad-spectrum drugs once the pathogen has been identified and sensitivities have been determined [34]. De-escalation minimizes the likelihood of resistance development, especially for essential antibiotics, which are frequently used in empirical therapy [35].

3. Antibiotic Restriction

Restricting the use of high-risk, broad-spectrum, or last-resort antibiotics is an effective technique for preventing resistance. AMS programs frequently contain formulary limits on specific antibiotics, which are only permitted under specified conditions or with the stewardship team's consent. This technique ensures that these effective antibiotics are administered sparingly, only for difficult-to-treat diseases or microorganisms that are resistant to other antibiotics [36, 37]. Carbapenems, cephalosporins, and polymyxins are some examples. Restricting their use lowers the risk of resistance developing in common diseases [38].

4. Empirical Therapy Guidelines

Empiric therapy is the first treatment given to a patient based on the most likely causal organism before laboratory findings become available. AMS programs create empiric therapeutic procedures that are specific to local resistance patterns and epidemiological data. These standards ensure that healthcare practitioners begin with an effective antibiotic while reducing the likelihood of resistance [39]. Empiric therapy guidelines aid in the prevention of broad-spectrum drug usage by focusing on the most likely pathogens and employing narrow-spectrum antibiotics whenever possible [40].

5. Dose Optimization

Optimizing antibiotic treatment doses and durations is crucial for improving therapeutic efficacy while avoiding resistance risks. Overdosing can increase the likelihood of side effects, whilst under dosing may fail to eliminate the infection and contribute to resistance [41]. AMS programs frequently highlight the necessity of dosage regimens tailored to patient variables such as renal function, age, and weight, as well as infection type. Shortening the duration of medication wherever possible is also recommended as prolonged antibiotic treatment can contribute to the selection of resistant organisms [42].

6. Point-of-Care Diagnostic Tests

Rapid diagnostic testing at the point of care can considerably enhance antibiotic prescribing by providing accurate information about the causing organism and its susceptibility. By diagnosing infections more precisely and rapidly, healthcare providers can make better antibiotic selection decisions and reduce overuse of broad-spectrum antibiotics [43]. Diagnostic studies for bacterial and viral infections, pathogen identification, and susceptibility testing can help clinicians provide better tailored treatment. When integrated into AMS programs, these tests aid to reduce empirical antibiotic prescribing and antibiotic misuse [44].

7. Prospective Audit and Feedback

Prospective audits of antibiotic prescriptions are a significant strategy in AMS initiatives. This strategy involves the AMS team reviewing ongoing antibiotic therapy and providing comments to prescribing professionals. The purpose is to verify that antibiotics are used correctly and to identify areas where changes may be necessary [45]. Feedback can be supplied in real time, advising doctors on de-escalation, alternate antibiotic options, or duration modifications based on the patient's clinical status and microbiological data. This technique reinforces healthy prescribing behaviours and can lead to more sensible antibiotic use over time [46].

8. Education & Training

Continuous education and training for healthcare providers is an essential component of AMS programs. Healthcare practitioners must grasp the significance of antimicrobial stewardship, the dangers associated with AMR, and the best practices for prescription antibiotics. Workshops, seminars, and access to the most recent guidelines and research on antibiotic use are all examples of educational programs. Furthermore, training helps healthcare personnel stay current on emerging infections and resistance patterns. By building a culture of stewardship through education, AMS programs enable healthcare personnel to make informed decisions that help to reduce AMR [47, 48].

9. Multidisciplinary Collaboration

Successful AMS programs require collaboration among a variety of healthcare professionals, including infectious disease specialists, microbiologists, pharmacists, and frontline physicians. This multidisciplinary team collaborates to create guidelines, audit prescribing procedures, evaluate patient cases, and provide suggestions for effective antibiotic use [49]. Collaboration is essential for developing an integrated approach to stewardship that covers all elements of antimicrobial usage, from diagnosis to treatment, monitoring, and de-escalation. By integrating numerous stakeholders, AMS programs ensure that different points of view are considered, resulting in more thorough and effective stewardship initiatives [50].

10. Surveillance and data collection

Continuous monitoring of antibiotic use and resistance patterns is critical for optimizing antimicrobial therapy. By collecting and evaluating data on antibiotic consumption, clinical outcomes, and resistance trends, AMS programs can identify areas for improvement [51]. Surveillance assists in updating local antibiotic guidelines to better reflect current resistance patterns and allows the program to assess the efficacy of stewardship actions. Regular reporting of antibiotic use and resistance data increases awareness among healthcare providers and emphasizes the importance of continuous stewardship measures [52].

The Role of Surveillance in AMS

Surveillance is a critical component of efficient AMS programs because it provides the necessary data to advise antimicrobial use decisions, guide treatment methods, and track the development of resistance. Healthcare facilities that carefully analyze both antimicrobial consumption and resistance patterns might gain significant insights into AMR trends and take proactive efforts to limit its spread [53]. Surveillance not only identifies high-risk locations in healthcare settings where resistant infections may emerge, but it also helps shape targeted actions that enhance patient outcomes while preserving the effectiveness of current medications (Fig. 1) [54]. Surveillance data on antimicrobial usage enables AMS programs to track the number and types of antibiotics prescribed across patient groups and clinical contexts. This information can help uncover trends of abuse, misuse, or improper prescribing practices, such as the frequent use of broad-spectrum antibiotics when narrower-spectrum drugs would be more appropriate [55, 56]. By recognizing these trends, AMS teams may create focused interventions to optimize antibiotic use and ensure that antibiotics are only provided when absolutely necessary, at the optimal dose, and for the correct period [57]. Monitoring resistance patterns is equally important in the fight against AMR. Surveillance systems monitor the incidence of resistant microorganisms, allowing healthcare facilities to stay current with local and regional resistance trends [58]. For example, monitoring the resistance trends of prevalent hospital-associated infections such as *Clostridium difficile*, *Staphylococcus aureus* (including MRSA), and *Escherichia coli* enables doctors to change empiric therapy guidelines based on the most recent data. This guarantees that antibiotics provided empirically are effective against the most common diseases and reduces the use of potentially needless broad-spectrum antibiotics [59]. Another significant advantage of surveillance is the ability to detect new infections. By regularly monitoring microbiological data from laboratory cultures, AMS systems can detect the emergence of novel resistant species, even if they are not yet common. This early discovery is crucial for healthcare facilities to change infection control policies and antibiotic prescribing guidelines before a resistant disease spreads [60 & 61]. Surveillance programs can also detect possible outbreaks or clusters of resistant diseases, allowing for a timely reaction that minimizes the spread of these infections in hospital settings [62].



Fig: 1 The role of surveillance in AMS

Challenges in Implementing AMS Programs

Despite the enormous benefits of AMS programs in lowering AMR and improving patient outcomes, its implementation presents a number of problems, particularly in resource-limited settings. These issues can diminish the effectiveness of AMS efforts, delaying or preventing widespread implementation [63]. This table 2 organizes the challenges into key issues, their consequences, and potential solutions, offering a clearer view of each obstacle's impact on AMS programs. The following are some of the major hurdles to the successful implementation of AMS programs:

1. Lack of resources

In many healthcare settings, particularly in low- and middle-income nations, insufficient resources make it difficult to execute AMS programs effectively. The lack of sophisticated diagnostic techniques such as quick microbiological testing, molecular diagnostic procedures, and PCR-based testing reduces the ability to identify organisms and establish their drug susceptibility [64]. Without timely and reliable diagnostic information, doctors are frequently compelled to rely on empirical antibiotic therapy, which can result in the overuse or misuse of broad-spectrum antibiotics. This delay in pathogen identification and susceptibility testing also makes it more difficult to discontinue antibiotic therapy once the causative organism has been identified, increasing the risk of antimicrobial resistance [65, 66].

2. Healthcare Provider Resistance

Healthcare practitioners, such as physicians, nurses, and pharmacists, may be hesitant to change their previous practices or feel unsure about applying AMS recommendations. This resistance might result from a lack of awareness or understanding of the significance of antimicrobial stewardship, especially in contexts where the hazards of AMR are not immediately apparent [67 & 68]. Clinicians may also be pressured by patients and their families to prescribe antibiotics when they are not medically necessary. In other circumstances, healthcare practitioners may be concerned about the perceived risk of patient dissatisfaction or noncompliance if antibiotics are not provided, causing a reluctance to follow AMS procedures [69].

3. Limited access to infection control resources

In some healthcare settings, particularly those with limited resources, infection prevention and control (IPC) strategies are either inadequate or nonexistent [70]. IPC procedures such as appropriate hand hygiene, isolation of sick patients, sterilization of medical equipment, and the use of personal protective equipment (PPE) are critical in avoiding the spread of resistant microbes in healthcare institutions [71]. Without strong IPC programs, resistant diseases can spread quickly, undermining the work of AMS initiatives. Healthcare facilities that do not have appropriate IPC resources are more likely to have outbreaks of resistant diseases, which can be disastrous for patient safety. The success of AMS programs depends on strengthening infection prevention measures and ensuring that IPC resources are available [72, 73].

4. Financial constraints

Implementing an AMS program necessitates an initial investment in a variety of resources, including personnel, training, monitoring infrastructure, and technology. For example, the program may necessitate the hiring of specialized AMS coordinators, pharmacists, microbiologists, and infectious disease specialists, all of whom must receive proper training and compensation [74, 75]. Furthermore, creating or enhancing laboratory diagnostic services, implementing surveillance systems to track antibiotic usage and resistance patterns and conducting frequent audits of antibiotic prescribing procedures necessitate financial investment. In resource-constrained environments where healthcare financing is already stressed, financial restrictions can be a significant impediment to the adoption and sustainability of AMS initiatives [76].

5. Cultural and structural barriers

In some healthcare settings, deep-rooted cultural and institutional traditions favour quick fixes, such as antibiotic prescriptions, over more complete diagnosis and treatment approaches. This is especially difficult in outpatient settings, as patients may expect immediate treatment in the form of antibiotics for ailments that do not warrant them, such as viral infections [77]. Furthermore, institutional constraints, such as a lack of interdisciplinary collaboration or communication between healthcare practitioners, may impede the efficient implementation of AMS techniques. Without a collaboration culture and a shared knowledge of the need of judicious antibiotic usage, incorporating AMS concepts into regular clinical practice becomes impossible [78].

6. Limited surveillance capacity

Effective surveillance is critical for monitoring antimicrobial usage, identifying resistance patterns, and detecting emergent concerns. However, many healthcare facilities, particularly those in low-resource settings, lack the infrastructure required to collect, analyze, and report data on antibiotic prescribing and resistance trends [79]. Surveillance systems are frequently inadequate, with insufficient capacity to collect real-time data that might inform therapeutic decisions. In the absence of extensive surveillance, identifying areas of overuse, misuse, or growing resistance trends is difficult, making targeted interventions and adjusting AMS methods tough [80].

7. Resistance from pharmaceutical companies

Pharmaceutical corporations may be reluctant to sponsor AMS programs due to financial considerations. For example, while promoting broad-spectrum antibiotics or novel antibiotic classes may benefit company profits, these activities may contribute to the emergence of resistance [81]. Furthermore, the high cost of newer antibiotics may limit their availability in certain healthcare settings, particularly in low-income areas. Negotiating with pharmaceutical firms to reconcile economic interests and public health objectives can be a difficult task for AMS programs [82].

8. Sociopolitical challenges

Political instability, a lack of official support, and poor healthcare systems can all be impediments to launching AMS programs in certain areas [83]. National health policies may fail to prioritize AMR, and antibiotic use standards may not be adequately regulated or enforced. In countries with political or economic constraints, prioritizing long-term AMR solutions might be challenging when competing acute healthcare demands exist [84].

Table: 2 The Challenges in Implementing AMS Programs

Challenge	Key Issues	Consequences	Solutions/Considerations	Ref
Cultural and Structural Barriers	- Preference for quick fixes like antibiotics - Patient pressure for antibiotics - Lack of interdisciplinary collaboration	- Overprescription of antibiotics for viral or minor conditions - Difficult integration of AMS practices into routine care	- Foster a collaborative culture - Educate patients and clinicians about appropriate antibiotic use	[85]
Limited Surveillance Capacity	- Insufficient infrastructure for data collection and analysis - Inadequate real-time monitoring of antibiotic use and resistance	- Inability to detect emerging resistance trends - Difficulty targeting areas of overuse or misuse	- Invest in surveillance infrastructure - Develop simpler, cost-effective surveillance methods	[86]
Resistance from Pharmaceutical Companies	- Financial interests may conflict with public health goals - High cost of newer antibiotics - Promotion of broad-spectrum antibiotics	- Limited access to novel antibiotics - Continued use of broad-spectrum drugs that contribute to resistance	- Negotiate for affordable antibiotic options - Advocate for a balance between public health and profit	[87]
Sociopolitical Challenges	- Political instability - Lack of government support - Poor regulation of antibiotic use	- Inconsistent implementation of AMS programs - Inability to regulate or enforce antibiotic standards	- Advocate for national policies prioritizing AMR - Strengthen health system resilience and infrastructure	[88,89]
Cultural and Structural Barriers	- Deep-rooted cultural and institutional traditions favoring quick fixes like antibiotics over thorough diagnosis. - Patient pressure for immediate antibiotic prescriptions, especially in outpatient settings. - Lack of interdisciplinary collaboration.	- Overprescription of antibiotics for conditions that don't warrant them (e.g., viral infections). - Impeded implementation of AMS strategies due to lack of cooperation.	- Encourage a collaborative culture across disciplines. - Educate patients on appropriate antibiotic use. - Implement cultural shifts in clinical practices.	[90]
Limited Surveillance Capacity	- Insufficient infrastructure for monitoring antibiotic use, resistance trends, and data collection. - Lack of real-time data for informed decision-making in low-resource settings.	- Difficulty in identifying overuse, misuse, and emerging resistance trends. - Hindered ability to tailor AMS interventions.	- Strengthen infrastructure for surveillance. - Develop cost-effective, simplified surveillance systems. - Encourage partnerships for data collection and analysis.	[86, 91]
Resistance from Pharmaceutical Companies	- Financial interests conflict with public health goals, such as promoting broad-spectrum antibiotics. - High cost of newer antibiotics, limiting access in low-income areas.	- Restricted availability of novel antibiotics. - Continued promotion of broad-spectrum antibiotics that contribute to resistance.	- Advocate for affordable access to antibiotics. - Collaborate with pharmaceutical companies to align public health goals with economic interests.	[92]
Sociopolitical Challenges	- Political instability, lack of official support, and poor	- Delay or prevent AMS program	- Advocate for stronger national policies on	[87,93, 94]

	healthcare systems can hinder AMS programs. - National policies may not prioritize AMR, and antibiotic use standards may not be well-regulated.	implementation. - Inconsistent or ineffective regulation of antibiotic usage.	AMR. - Promote the integration of AMR priorities in healthcare reform. - Strengthen healthcare systems in unstable regions.	

Impact of AMS on Patient Outcomes

AMS programs are increasingly being recognized for their ability to enhance patient outcomes, not only by assuring proper antibiotic use, but also by reducing the spread of AMR inside healthcare systems. The following are the primary ways in which AMS programs effectively improve patient care:

1. Reduced mortality

Optimizing antimicrobial medication through AMS programs improves clinical outcomes, particularly in patients with resistant pathogen infections. Infections caused by resistant organisms are frequently more difficult to cure and lead to greater fatality rates [95]. AMS programs can improve treatment outcomes by ensuring that patients receive the appropriate antibiotic therapy, which is personalized to the specific pathogen and its susceptibility profile [96]. Furthermore, rapid de-escalation of broad-spectrum antibiotics after the pathogen has been identified not only saves wasteful medication use, but also helps to reduce treatment failures and related consequences [97].

2. Shorter hospital stays

One of the most noticeable effects of AMS programs is a reduction in hospital length of stay. By optimizing antibiotic use, such as avoiding unneeded or prolonged antibiotic medication and ensuring de-escalation when necessary, AMS programs can assist to reduce the risk of complications, adverse drug reactions, and treatment failures. Shorter durations of improper antibiotic therapy are connected with faster recovery times, which directly lead to shorter hospital stays [41, 98]. Furthermore, by emphasizing the proper administration of antibiotics, AMS programs can help reduce the development of secondary infections and problems such as *Clostridium difficile* infections, which are known to lengthen hospital stays. Finally, shorter hospital stays improve patient outcomes while simultaneously easing the demand on healthcare resources [99, 100].

3. Improved resistance profiles

Effective AMS programs help to improve resistance profiles by lowering the frequency of resistant illnesses in both hospital and community settings. The prudent use of antibiotics helps to delay the emergence and spread of resistant germs, making treatments more effective for future patients. Antibiotics are provided correctly, with appropriate dose, duration, and targeting, to reduce the selective pressure that causes resistance development. Over time, reducing the use of broad-spectrum antibiotics and promoting narrow-spectrum medicines, guided by culture and susceptibility data, can improve the facility's overall microbial resistance pattern. This helps to provide more predictable and effective treatment options for patients, lowering the risk of infections caused by difficult-to-treat, resistant microorganisms [4,17, 101].

4. Cost savings

While AMS systems involve an initial investment in staff, training, surveillance, and infrastructure, they produce significant long-term cost reductions. By reducing unnecessary antibiotic prescriptions and minimizing adverse drug events associated with improper antibiotic usage, AMS programs can reduce healthcare expenses associated with medication-related problems, extended hospital stays, and the management of resistant infections. Reduced antibiotic consumption translates with lower drug prices, especially for pricey broad-spectrum antibiotics or last-resort therapy. Furthermore, by avoiding or limiting the transmission of resistant diseases, AMS initiatives contribute to lowering the financial burden of treating complicated, multi-drug-resistant infections, which are frequently more expensive to manage [102,103].

Future Directions

The future of AMS programs is becoming increasingly dependent on breakthroughs that combine cutting-edge technology, improved diagnostic procedures, and international collaboration [104]. Artificial intelligence (AI) and machine learning (ML) are expected to play critical roles in forecasting antibiotic resistance patterns, optimizing antibiotic dosing, and personalizing therapies in real-time. By evaluating clinical data, AI can assist physicians in making data-driven decisions that improve patient outcomes and reduce resistance development [105]. Furthermore, rapid diagnostic tests (RDTs) and antimicrobial biomarkers will enable faster pathogen identification and more precise antibiotic therapy, minimizing wasteful use and increasing treatment efficacy [106]. Genomic monitoring will allow for real-time tracking of resistance at the genetic level, assisting healthcare systems in identifying emerging resistant strains and refining treatment protocols in response to local resistance patterns. Furthermore, global collaboration is critical in combating AMR worldwide [107]. Strengthened international collaboration and policy development are required to regulate antibiotic usage across industries and share surveillance data in order to tackle AMR on a global scale [21]. In resource-constrained settings, point-of-care testing and mobile health technology show potential for enhancing diagnostic accuracy and antibiotic stewardship. Finally, investigating alternative treatments such as phage therapy and antimicrobial peptides provides promising answers for treating resistant illnesses while lowering reliance on standard antibiotics [108]. This table 3 shows how each advancement will specifically address a different aspect of antimicrobial stewardship, such as diagnostic speed, global policy, and alternative treatment options, and their resulting impact on patient outcomes.

Table: 3 Future aspects of antimicrobial stewardship

Advancement	Technology/Method	Benefit to AMS	Impact on Patient Outcomes	Ref
Artificial Intelligence (AI) & Machine Learning	Predictive algorithms, real-time data analysis	Improves decision-making by predicting resistance and recommending therapies	Faster, more accurate treatments leading to reduced mortality rates	[109]
Rapid Diagnostic Testing	PCR-based tests, point-of-care diagnostics	Speeds up pathogen identification and susceptibility testing	Reduces inappropriate antibiotic use, shortens hospital stays	[110]
Genomic Surveillance	Whole-genome sequencing, resistance gene mapping	Tracks resistance trends and emerging pathogens across regions	Helps in providing tailored treatments, preventing resistance spread	[107]
Global Collaboration and Policy Development	International health policies, multi-sector partnerships	Standardizes global AMR responses, improves antibiotic regulations	Reduces global resistance rates, improving overall healthcare outcomes	[111]
Point-of-Care Testing & Health	Portable diagnostic devices, mobile health apps	Enhances access to diagnostics and stewardship tools in low-resource areas	Increases treatment accuracy, reduces unnecessary antibiotic prescriptions	[112]
Phage Therapy & Alternative Treatments	Bacteriophages, antimicrobial peptides	Provides alternative treatments for multi-drug-resistant infections	Expands treatment options for hard-to-treat infections, reducing reliance on antibiotics	[113]

Conclusion

Antimicrobial resistance is a significant worldwide health problem, highlighting the importance of comprehensive antimicrobial stewardship initiatives. These programs have demonstrated efficacy in optimizing antibiotic use, minimizing resistance, and improving patient outcomes while cutting healthcare costs. Key tactics for managing resistant infections include evidence-based prescribing, antibiotic de-escalation, and dose optimization. However, problems remain, particularly in resource-limited areas where diagnostic limitations, healthcare provider reluctance, and financial limits impede complete program implementation. Technological advancements such as artificial intelligence, quick diagnostic tools, and genomic surveillance show enormous promise for improving AMS efforts by allowing more precise and timely interventions. Furthermore, worldwide collaboration and policy development are essential for combating AMR across healthcare systems and businesses. The expansion and evolution of AMS programs are critical to combating AMR, ensuring antibiotic efficacy, and preserving public health. A coordinated, multi-level effort is required to ensure the future of antimicrobial medicines.

References

1. Salam MA, Al-Amin MY, Salam MT, Pawar JS, Akhter N, Rabaan AA, Alqumber MA. Antimicrobial resistance: a growing serious threat for global public health. InHealthcare 2023 Jan (Vol. 11, No. 13, p. 1946). Multidisciplinary Digital Publishing Institute.
2. Tang KW, Millar BC, Moore JE. Antimicrobial resistance (AMR). British journal of biomedical science. 2023 Jun 28;80:11387.
3. Dhingra S, Rahman NA, Peile E, Rahman M, Sartelli M, Hassali MA, Islam T, Islam S, Haque M. Microbial resistance movements: an overview of global public health threats posed by antimicrobial resistance, and how best to counter. Frontiers in public health. 2020 Nov 4;8:535668.
4. Muteeb G, Rehman MT, Shahwan M, Aatif M. Origin of antibiotics and antibiotic resistance, and their impacts on drug development: A narrative review. Pharmaceuticals. 2023 Nov 15;16(11):1615.
5. Tang KW, Millar BC, Moore JE. Antimicrobial resistance (AMR). British journal of biomedical science. 2023 Jun 28;80:11387.
6. Chokshi A, Sifri Z, Cennimo D, Horng H. Global contributors to antibiotic resistance. Journal of global infectious diseases. 2019 Jan 1;11(1):36-42.
7. Huemer M, Mairpady Shambat S, Brugger SD, Zinkernagel AS. Antibiotic resistance and persistence—Implications for human health and treatment perspectives. EMBO reports. 2020 Dec 3;21(12):e51034.
8. Economou V, Gousia P. Agriculture and food animals as a source of antimicrobial-resistant bacteria. Infection and drug resistance. 2015 Apr 1:49-61.
9. Muhaj FF, George SJ, Nguyen CD, Tyring SK. Antimicrobials and resistance part II: Antifungals, antivirals, and antiparasitics. Journal of the American Academy of Dermatology. 2022 Jun 1;86(6):1207-26.
10. Ahmed SK, Hussein S, Qurbani K, Ibrahim RH, Fareeq A, Mahmood KA, Mohamed MG. Antimicrobial resistance: Impacts, challenges, and future prospects. Journal of Medicine, Surgery, and Public Health. 2024 Apr 1;2:100081.
11. Giraldi G, Montesano M, Napoli C, Frati P, La Russa R, Santurro A, Scopetti M, Orsi GB. Healthcare-associated infections due to multidrug-resistant organisms: a surveillance study on extra hospital stay and direct costs. Current pharmaceutical biotechnology. 2019 Jul 1;20(8):643-52.
12. Kakkar AK, Shafiq N, Singh G, Ray P, Gautam V, Agarwal R, Muralidharan J, Arora P. Antimicrobial stewardship programs in resource constrained environments: understanding and addressing the need of the systems. Frontiers in public health. 2020 Apr 28;8:140.
13. Brink AJ. Antimicrobial stewardship (AMS) in the community. Clinical Pulmonary Medicine. 2016 Jan 1;23(1):1-0.

14. Salah A, El-Housseiny G, Elleboudy N, Yassien M. Antimicrobial stewardship programs: A review. Archives of Pharmaceutical Sciences Ain Shams University. 2021 Jun 1;5(1):143-57.
15. Rizvi TF. Exploring the role of community pharmacists in antimicrobial stewardship (Doctoral dissertation, University of Tasmania).
16. Noyes NR, Slizovskiy IB, Singer RS. Beyond antimicrobial use: a framework for prioritizing antimicrobial resistance interventions. Annual Review of Animal Biosciences. 2021 Feb 15;9(1):313-32.
17. Zakhour J, Haddad SF, Kerbage A, Wertheim H, Tattevin P, Voss A, Ünal S, Ouedraogo AS, Kanj SS. Diagnostic stewardship in infectious diseases: a continuum of antimicrobial stewardship in the fight against antimicrobial resistance. International journal of antimicrobial agents. 2023 Jul 1;62(1):106816.
18. Wu JH, Khalid F, Langford BJ, Beahm NP, McIntyre M, Schwartz KL, Garber G, Leung V. Community pharmacist prescribing of antimicrobials: a systematic review from an antimicrobial stewardship perspective. Canadian Pharmacists Journal/Revue des Pharmaciens du Canada. 2021 May;154(3):179-92.
19. Emberger J, Tassone D, Stevens MP, Markley JD. The current state of antimicrobial stewardship: challenges, successes, and future directions. Current infectious disease reports. 2018 Sep;20:1-2.
20. Aina BA, Ismail FB, Adediran OE, Sheba OO, Fasoyin MO. The importance of antimicrobial stewardship (AMS) in the mitigation of antimicrobial resistance (AMR). West African Journal of Pharmacy. 2024 Nov 7;35(2):1-0.
21. Shedeed E. Mapping Global Governance of Antibiotic Stewardship: A One Health Multi-Level Governance Approach (Doctoral dissertation, Université d'Ottawa| University of Ottawa).
22. Hwang S, Kwon KT. Core elements for successful implementation of antimicrobial stewardship programs. Infection & chemotherapy. 2021 Sep 17;53(3):421.
23. Sanchez GV. Core elements of outpatient antibiotic stewardship. MMWR. Recommendations and Reports. 2016;65.
24. Pulcini C, Binda F, Lamkang AS, Trett A, Charani E, Goff DA, Harbarth S, Hinrichsen SL, Levy-Hara G, Mendelson M, Nathwani D. Developing core elements and checklist items for global hospital antimicrobial stewardship programmes: a consensus approach. Clinical Microbiology and Infection. 2019 Jan 1;25(1):20-5.
25. Pulcini C, Binda F, Lamkang AS, Trett A, Charani E, Goff DA, Harbarth S, Hinrichsen SL, Levy-Hara G, Mendelson M, Nathwani D. Developing core elements and checklist items for global hospital antimicrobial stewardship programmes: a consensus approach. Clinical Microbiology and Infection. 2019 Jan 1;25(1):20-5.
26. Borek AJ, Campbell A, Dent E, Moore M, Butler CC, Holmes A, Walker AS, McLeod M, Tonkin-Crine S. Development of an intervention to support the implementation of evidence-based strategies for optimising antibiotic prescribing in general practice. Implementation science communications. 2021 Dec;2:1-6.
27. Satterfield J, Miesner AR, Percival KM. The role of education in antimicrobial stewardship. Journal of Hospital Infection. 2020 Jun 1;105(2):130-41.
28. Tacconelli E, Sifakis F, Harbarth S, Schrijver R, van Mourik M, Voss A, Sharland M, Rajendran NB, Rodríguez-Baño J, Bielicki J, de Kraker M. Surveillance for control of antimicrobial resistance. The Lancet Infectious Diseases. 2018 Mar 1;18(3):e99-106.
29. Koroluk KJ. Community Pharmacists as Antimicrobial Stewards: A Focus on Acute Otitis Media (Master's thesis, University of Toronto (Canada)).
30. Khader Y, Alyahya M, Saadeh R. Water, Sanitation, and Hygiene (WASH) and Infection Prevention and Control (IPC) in Primary. Primary Health Care. 2022 Mar 16:229.
31. Özgenç O. Methodology in improving antibiotic implementation policies. World Journal of Methodology. 2016 Jun 26;6(2):143.

32. Capuozzo M, Zovi A, Langella R, Ottaiano A, Cascella M, Scognamiglio M, Ferrara F. Optimizing antibiotic use: Addressing resistance through effective strategies and health policies. Antibiotics. 2024 Nov 21;13(12):1112.
33. De With K, Allerberger F, Amann S, Apfalter P, Brodt HR, Eckmanns T, Fellhauer M, Geiss HK, Janata O, Krause R, Lemmen S. Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases. Infection. 2016 Jun;44:395-439.
34. Alshareef H, Alfahad W, Albaadani A, Alyazid H, Talib RB. Impact of antibiotic de-escalation on hospitalized patients with urinary tract infections: A retrospective cohort single center study. Journal of Infection and Public Health. 2020 Jul 1;13(7):985-90.
35. Rapti V, Poulakou G, Mousouli A, Kakasis A, Pagoni S, Pechlivanidou E, Masgala A, Sympardi S, Apostolopoulos V, Giannopoulos C, Alexiou N. Assessment of De-Escalation of Empirical Antimicrobial Therapy in Medical Wards with Recognized Prevalence of Multi-Drug-Resistant Pathogens: A Multicenter Prospective Cohort Study in Non-ICU Patients with Microbiologically Documented Infection. Antibiotics. 2024 Aug 27;13(9):812.
36. Giamarellou H, Galani L, Karavasilis T, Ioannidis K, Karaiskos I. Antimicrobial stewardship in the hospital setting: a narrative review. Antibiotics. 2023 Oct 21;12(10):1557.
37. Mustafa G, Pignatello R. Antimicrobial Stewardship: New Insights. BoD–Books on Demand; 2024 Jun 26.
38. Elshamy AA, Aboshanab KM. A review on bacterial resistance to carbapenems: epidemiology, detection and treatment options. Future science OA. 2020 Mar 1;6(3):FSO438.
39. Osih RB, McGregor JC, Rich SE, Moore AC, Furuno JP, Perencevich EN, Harris AD. Impact of empiric antibiotic therapy on outcomes in patients with Pseudomonas aeruginosa bacteremia. Antimicrobial agents and chemotherapy. 2007 Mar;51(3):839-44.
40. Singhal T. "Rationalization of empiric antibiotic therapy"–a move towards preventing emergence of resistant infections. The Indian Journal of Pediatrics. 2020 Nov;87(11):945-50.
41. Bassetti S, Tschudin-Sutter S, Egli A, Osthoff M. Optimizing antibiotic therapies to reduce the risk of bacterial resistance. European journal of internal medicine. 2022 May 1;99:7-12.
42. Hall RK, Kazancıoğlu R, Thanachayanont T, Wong G, Sabanayagam D, Battistella M, Ahmed SB, Inker LA, Barreto EF, Fu EL, Clase CM. Drug stewardship in chronic kidney disease to achieve effective and safe medication use. Nature Reviews Nephrology. 2024 Jun;20(6):386-401.
43. Dhesi Z, Enne VI, O 'Grady J, Gant V, Livermore DM. Rapid and point-of-care testing in respiratory tract infections: an antibiotic guardian?. ACS Pharmacology & Translational Science. 2020 May 12;3(3):401-17.
44. Maurer FP, Christner M, Hentschke M, Rohde H. Advances in rapid identification and susceptibility testing of bacteria in the clinical microbiology laboratory: implications for patient care and antimicrobial stewardship programs. Infectious disease reports. 2017 Mar 30;9(1):6839.
45. Cassim J, Essack SY, Chetty S. An audit of antibiotic prescriptions: an antimicrobial stewardship pre-implementation study at a tertiary care public hospital. JAC-Antimicrobial Resistance. 2025 Feb;7(1):dlae219.
46. Cusack R, Little E, Martin-Loeches I. Practical lessons on antimicrobial therapy for critically Ill patients. Antibiotics. 2024 Feb 6;13(2):162.
47. Gyssens IC. Role of education in antimicrobial stewardship. Medical Clinics. 2018 Sep 1;102(5):855-71
48. Abimbola SO, Otieno MA, Cole J. Reducing the use of antimicrobials as a solution to the challenge of antimicrobial resistance (AMR): approaching an ethical dilemma through the lens of planetary health. Challenges. 2021 Sep 13;12(2):23.
49. Goff DA, Kullar R, Goldstein EJ, Gilchrist M, Nathwani D, Cheng AC, Cairns KA, Escandón-Vargas K, Villegas MV, Brink A, van den Bergh D. A global call from five countries to

collaborate in antibiotic stewardship: united we succeed, divided we might fail. The Lancet Infectious Diseases. 2017 Feb 1;17(2):e56-63.

50. Thursky KA, Hardefeldt LY, Rajkhowa A, Ierano C, Bishop J, Hawes L, Biezen R, Saha SK, Dowson L, Bailey KE, Scarborough R. Antimicrobial stewardship in Australia: the role of qualitative research in programme development. JAC-Antimicrobial Resistance. 2021 Dec 1;3(4):dlab166.
51. Vieceli T, Rello J. Optimization of antimicrobial prescription in the hospital. European Journal of Internal Medicine. 2022 Dec 1;106:39-44.
52. Al-Omari A, Al Mutair A, Alhumaid S, Salih S, Alanazi A, Albarsan H, Abourayan M, Al Subaie M. The impact of antimicrobial stewardship program implementation at four tertiary private hospitals: results of a five-years pre-post analysis. Antimicrobial Resistance & Infection Control. 2020 Jun 29;9(1):95.
53. Sanders P, Vanderhaeghen W, Fertner M, Fuchs K, Obritzhauser W, Agunos A, Carson C, Borck Høg B, Dalhoff Andersen V, Chauvin C, Hémonic A. Monitoring of farm-level antimicrobial use to guide stewardship: overview of existing systems and analysis of key components and processes. Frontiers in veterinary science. 2020 Aug 21;7:540.
54. Struelens MJ, Ludden C, Werner G, Sintchenko V, Jokelainen P, Ip M. Real-time genomic surveillance for enhanced control of infectious diseases and antimicrobial resistance. Frontiers in Science. 2024 Apr 25;2:1298248.
55. Cantón R, Gottlieb T, Coombs GW, Woo PC, Korman TM, Garcia-Castillo M, Daley D, Bauer KA, Wong M, Wolf DJ, Siddiqui F. Antimicrobial surveillance: A 20-year history of the SMART approach to addressing global antimicrobial resistance into the future. International Journal of Antimicrobial Agents. 2023 Dec 1;62(6):107014.
56. Desai A. Exploring trends in antibiotic use and resistance in a district, regional and tertiary hospital in the umgungundlovu district (Doctoral dissertation, University of KwaZulu-Natal, Westville).
57. Hall J, Hawkins O, Montgomery A, Singh S, Mullan J, Degeling C. Dismantling antibiotic infrastructures in residential aged care: the invisible work of antimicrobial stewardship (AMS). Social Science & Medicine. 2022 Jul 1;305:115094.
58. Oliveira M, Antunes W, Mota S, Madureira-Carvalho Á, Dinis-Oliveira RJ, da Silva DD. An overview of the recent advances in antimicrobial resistance. Microorganisms. 2024 Sep 21;12(9):1920.
59. Kourbeti I, Kamiliou A, Samarkos M. Antibiotic stewardship in surgical departments. Antibiotics. 2024 Apr 4;13(4):329.
60. Jia P, Liu S, Yang S. Innovations in public health surveillance for emerging infections. Annual Review of Public Health. 2023 Apr 3;44(1):55-74.
61. Wenzler E, Maximos M, Asempa TE, Biehle L, Schuetz AN, Hirsch EB. Antimicrobial susceptibility testing: An updated primer for clinicians in the era of antimicrobial resistance: Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023 Apr;43(4):264-78.
62. Avershina E, Shapovalova V, Shipulin G. Fighting antibiotic resistance in hospital-acquired infections: current state and emerging technologies in disease prevention, diagnostics and therapy. Frontiers in microbiology. 2021 Jul 21;12:707330.
63. Monmaturapoj T. ANTIMICROBIAL STEWARDSHIP IN HOSPITALS: AN EXPLORATION OF FACTORS THAT INFLUENCE OR CONTRIBUTE TO THE IMPLEMENTATION OF THE INITIATIVE.
64. Kakkar AK, Shafiq N, Singh G, Ray P, Gautam V, Agarwal R, Muralidharan J, Arora P. Antimicrobial stewardship programs in resource constrained environments: understanding and addressing the need of the systems. Frontiers in public health. 2020 Apr 28;8:140.
65. Vasala A, Hytönen VP, Laitinen OH. Modern tools for rapid diagnostics of antimicrobial resistance. Frontiers in cellular and infection microbiology. 2020 Jul 15;10:308.

66. Panthöfer S. Do doctors prescribe antibiotics out of fear of malpractice?. Journal of Empirical Legal Studies. 2022 Jun;19(2):340-81.
67. Burton E, O'Driscoll M, Fleming A. The protected antimicrobial process in a University Teaching Hospital: a qualitative interview study exploring the knowledge, attitudes, and experiences of healthcare professionals. International Journal of Clinical Pharmacy. 2022 Jun;44(3):630-40.
68. Stivers T. Prescribing under pressure: Parent-physician conversations and antibiotics. Oxford University Press; 2007 Mar 1.
69. Pechère JC, Hughes D, Kardas P, Cornaglia G. Non-compliance with antibiotic therapy for acute community infections: a global survey. International journal of antimicrobial agents. 2007 Mar 1;29(3):245-53.
70. Adams V, Song J, Shang J, McDonald M, Dowding D, Ojo M, Russell D. Infection prevention and control practices in the home environment: Examining enablers and barriers to adherence among home health care nurses. American journal of infection control. 2021 Jun 1;49(6):721-6.
71. Morris H, Murray R. Healthcare, hygiene, and personal protective equipment (PPE). InMedical Textiles 2021 Dec 21 (pp. 261-310). CRC Press.
72. Mudenda S, Chabalenge B, Daka V, Mfune RL, Salachi KI, Mohamed S, Mufwambi W, Kasanga M, Matafwali SK. Global strategies to combat antimicrobial resistance: a one health perspective. Pharmacology & Pharmacy. 2023 Aug 18;14(8):271-328.
73. Gilbert GL, Kerridge I. Hospital infection prevention and control (IPC) and antimicrobial stewardship (AMS): dual strategies to reduce antibiotic resistance (ABR) in hospitals. Ethics and Drug Resistance: collective responsibility for global Public Health. 2020:89-108.
74. Hijazi K, Joshi C, Gould IM. Challenges and opportunities for antimicrobial stewardship in resource-rich and resource-limited countries. Expert Review of Anti-infective Therapy. 2019 Aug 3;17(8):621-34.
75. Nelson GE, Narayanan N, Onguti S, Stanley K, Newland JG, Doernberg SB. Principles and practice of antimicrobial stewardship program resource allocation. Infectious Disease Clinics. 2023 Dec 1;37(4):683-714.
76. Majumder MA, Rahman S, Cohall D, Bharatha A, Singh K, Haque M, Gittens-St Hilaire M. Antimicrobial stewardship: fighting antimicrobial resistance and protecting global public health. Infection and drug resistance. 2020 Dec 29:4713-38.
77. Sowemimo A. Divided: Racism, medicine and why we need to decolonise healthcare. Profile Books; 2023 Apr 6.
78. Aika IN, Enato E. Health care systems administrators perspectives on antimicrobial stewardship and infection prevention and control programs across three healthcare levels: a qualitative study. Antimicrobial Resistance & Infection Control. 2022 Dec 10;11(1):157.
79. Rony MK, Sharmi PD, Alamgir HM. Addressing antimicrobial resistance in low and middle-income countries: overcoming challenges and implementing effective strategies. Environmental Science and Pollution Research. 2023 Sep;30(45):101896-902.
80. Castaneda C, Nalley K, Mannion C, Bhattacharyya P, Blake P, Pecora A, Goy A, Suh KS. Clinical decision support systems for improving diagnostic accuracy and achieving precision medicine. Journal of clinical bioinformatics. 2015 Dec;5:1-6.
81. Dutescu IA, Hillier SA. Encouraging the development of new antibiotics: are financial incentives the right way forward? A systematic review and case study. Infection and drug resistance. 2021 Feb 5:415-34.
82. Mendelson M, Røttingen JA, Gopinathan U, Hamer DH, Wertheim H, Basnyat B, Butler C, Tomson G, Balasegaram M. Maximising access to achieve appropriate human antimicrobial use in low-income and middle-income countries. The Lancet. 2016 Jan 9;387(10014):188-98.
83. Limato R, Broom A, Nelwan EJ, Hamers RL. A qualitative study of barriers to antimicrobial stewardship in Indonesian hospitals: governance, competing interests, cost, and structural vulnerability. Antimicrobial Resistance & Infection Control. 2022 Jun 14;11(1):85.

84. Bonnifield RS, Klemperer K. The Not-So-Invisible Hand of “Stewardship,” Within and Beyond Antibiotics: Implications of Non-Monetary Pharmaceutical Controls for Access to Medicines. Center for Global Development; 2023 Aug 7.
85. Ledingham K, Hinchliffe S, Jackson M, Thomas F, Tomson G. Antibiotic resistance: using a cultural contexts of health approach to address a global health challenge. World Health Organization. 2019 Dec 4.
86. Frost I, Kapoor G, Craig J, Liu D, Laxminarayan R. Status, challenges and gaps in antimicrobial resistance surveillance around the world. Journal of global antimicrobial resistance. 2021 Jun 1;25:222-6.
87. Luepke KH, Suda KJ, Boucher H, Russo RL, Bonney MW, Hunt TD, Mohr III JF. Past, present, and future of antibacterial economics: increasing bacterial resistance, limited antibiotic pipeline, and societal implications. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2017 Jan;37(1):71-84.
88. Sanders D. The struggle for health: medicine and the politics of underdevelopment. Oxford University Press; 2023 Feb 27.
89. Degeling C, Johnson J, Kerridge I, Wilson A, Ward M, Stewart C, Gilbert G. Implementing a One Health approach to emerging infectious disease: reflections on the socio-political, ethical and legal dimensions. BMC Public Health. 2015 Dec;15:1-1.
90. Riad M. Study of the modern role of pharmacists in the rational use of medicines.
91. Kiyasseh D, Zhu T, Clifton D. The promise of clinical decision support systems targetting low-resource settings. IEEE Reviews in Biomedical Engineering. 2020 Aug 19;15:354-71.
92. Adebisi YA. Balancing the risks and benefits of antibiotic use in a globalized world: the ethics of antimicrobial resistance. Globalization and Health. 2023 Apr 20;19(1):27.
93. Luepke KH, Suda KJ, Boucher H, Russo RL, Bonney MW, Hunt TD, Mohr III JF. Past, present, and future of antibacterial economics: increasing bacterial resistance, limited antibiotic pipeline, and societal implications. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2017 Jan;37(1):71-84.
94. Chioro A, Coll-Seck AM, Høie B, Moeloek N, Motsoaledi A, Rajatanavin R, Touraine M. Antimicrobial resistance: a priority for global health action. Bulletin of the World Health Organization. 2015;93:439-.
95. Vieceli T, Rello J. Optimization of antimicrobial prescription in the hospital. European Journal of Internal Medicine. 2022 Dec 1;106:39-44.
96. Mancuso G, Midiri A, Gerace E, Biondo C. Bacterial antibiotic resistance: the most critical pathogens. Pathogens. 2021 Oct 12;10(10):1310.
97. Dumkow LE, Worden LJ, Rao SN. Syndromic diagnostic testing: a new way to approach patient care in the treatment of infectious diseases. Journal of Antimicrobial Chemotherapy. 2021 Sep 1;76(Supplement_3):iii4-11.
98. Bassetti S, Tschudin-Sutter S, Egli A, Osthoff M. Optimizing antibiotic therapies to reduce the risk of bacterial resistance. European journal of internal medicine. 2022 May 1;99:7-12.
99. Schönherr SG, Ranft D, Lippmann N, Lübbert C. Changes in antibiotic consumption, AMR and Clostridioides difficile infections in a large tertiary-care center following the implementation of institution-specific guidelines for antimicrobial therapy: a nine-year interrupted time series study. PLoS One. 2021 Oct 14;16(10):e0258690.
100. Aina BA, Ismail FB, Adediran OE, Sheba OO, Fasoyin MO. The importance of antimicrobial stewardship (AMS) in the mitigation of antimicrobial resistance (AMR). West African Journal of Pharmacy. 2024 Nov 7;35(2):1-0.
101. Leung V, Ashiru-Oredope D, Hicks L, Kabbani S, Aloosh M, Armstrong IE, Brown KA, Daneman N, Lam K, Meghani H, Nur M. Leveraging local public health to advance antimicrobial stewardship (AMS) implementation and mitigate antimicrobial resistance (AMR): a scoping review. JAC-Antimicrobial Resistance. 2024 Dec;6(6):dlae187.
102. Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of adverse events with antibiotic use in hospitalized patients. JAMA internal medicine. 2017 Sep 1;177(9):1308-15.

103. McDonnell A, Dissanayake R, Klemperer K, Toxvaerd F, Sharland M. The economics of antibiotic resistance. Center for Global Development; 2024 Feb 22.
104. de Magalhães AA, Santos AT. Advancements in Diagnostic Methods and Imaging Technologies in Dentistry: A Literature Review of Emerging Approaches. Journal of Clinical Medicine. 2025 Feb 14;14(4):1277.
105. Pennisi F, Pinto A, Ricciardi GE, Signorelli C, Gianfredi V. The Role of Artificial Intelligence and Machine Learning Models in Antimicrobial Stewardship in Public Health: A Narrative Review. Antibiotics. 2025 Jan 30;14(2):134.
106. Vasala A, Hytönen VP, Laitinen OH. Modern tools for rapid diagnostics of antimicrobial resistance. Frontiers in cellular and infection microbiology. 2020 Jul 15;10:308.
107. Gardy JL, Loman NJ. Towards a genomics-informed, real-time, global pathogen surveillance system. Nature Reviews Genetics. 2018 Jan;19(1):9-20.
108. Lin DM, Koskella B, Lin HC. Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. World journal of gastrointestinal pharmacology and therapeutics. 2017 Aug 6;8(3):162.
109. de la Lastra JM, Wardell SJ, Pal T, de la Fuente-Nunez C, Pletzer D. From data to decisions: Leveraging artificial intelligence and machine learning in combating antimicrobial resistance–A comprehensive review. Journal of medical systems. 2024 Aug 1;48(1):71.
110. Reali S, Najib EY, Balázs KE, Tan AC, Váradi L, Hibbs DE, Groundwater PW. Novel diagnostics for point-of-care bacterial detection and identification. RSC advances. 2019;9(37):21486-97.
111. Aslam B, Asghar R, Muzammil S, Shafique M, Siddique AB, Khurshid M, Ijaz M, Rasool MH, Chaudhry TH, Aamir A, Baloch Z. AMR and Sustainable Development Goals: at a crossroads. Globalization and Health. 2024 Oct 17;20(1):73.
112. Olatunji AO, Olaboye JA, Maha CC, Kolawole TO, Abdul S. Revolutionizing infectious disease management in low-resource settings: The impact of rapid diagnostic technologies and portable devices. International Journal of Applied Research in Social Sciences. 2024;6(7):1417-32.
113. Iszatt JJ, Larcombe AN, Chan HK, Stick SM, Garratt LW, Kicic A. Phage therapy for multi-drug resistant respiratory tract infections. Viruses. 2021 Sep 11;13(9):1809.